Rigel Pharmaceuticals is trading higher after entering an exclusive global licensing agreement with Arvinas and Pfizer for the oral PROTAC drug VEPPANU (vepdegestrant). The deal is a positive strategic development for Rigel and supports its pipeline positioning in oncology-focused biotech. The move is likely to influence Rigel shares more than the broader market.
Rigel Pharmaceuticals is trading higher after entering an exclusive global licensing agreement with Arvinas and Pfizer for the oral PROTAC drug VEPPANU (vepdegestrant). The deal is a positive strategic development for Rigel and supports its pipeline positioning in oncology-focused biotech. The move is likely to influence Rigel shares more than the broader market.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
moderately positive
Sentiment Score
0.55
Ticker Sentiment
